Compare JBI & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBI | ABUS |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.0M | 848.8M |
| IPO Year | 2021 | 2008 |
| Metric | JBI | ABUS |
|---|---|---|
| Price | $4.86 | $4.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.17 | $5.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.6M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.26 |
| EPS | N/A | ★ 0.87 |
| Revenue | N/A | ★ $14,083,000.00 |
| Revenue This Year | $9.36 | N/A |
| Revenue Next Year | $3.16 | $239.71 |
| P/E Ratio | $12.96 | ★ $4.87 |
| Revenue Growth | N/A | ★ 128.21 |
| 52 Week Low | $4.26 | $3.04 |
| 52 Week High | $10.80 | $5.10 |
| Indicator | JBI | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 38.80 | 41.74 |
| Support Level | N/A | $3.68 |
| Resistance Level | $5.66 | $4.62 |
| Average True Range (ATR) | 0.27 | 0.15 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 48.95 | 30.19 |
Janus International Group Inc is a manufacturer and supplier of turnkey solutions for self-storage, commercial, and industrial building Solutions. The company provides products that include roll-up and swing doors, hallway systems, relocatable storage MASS (Moveable Additional Storage Structures) units, and technologies for automating facility and door operation. It is operated through two geographic regions; Janus North America and Janus International. The Janus International segment is comprised of a subsidiary whose production and sales are largely in Europe and Australia. The Janus North America segment is comprised of all the other entities.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.